Fwd: Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 19;
Leinonen M, Kotaniemi-Talonen L, Anttila A, Dyba T, Tarkkanen J, Nieminen P

A persistent high-risk human papillomavirus (hrHPV) infection is a necessary condition for developing a cervical intraepithelial neoplasia and cervical cancer. The viral aetiology in cervical carcinogenesis has stimulated attempts to use HPV DNA detection in cervical cancer screening. In Finland there is an ongoing study assessing the benefits of primary HPV DNA testing in the setting of centrally organised mass screening for cervical cancer. Here we present the age-specific prevalence of hrHPV infection and associated sociodemographic factors of 16,895 women aged 25-65 years attending the 5-yearly cervical cancer screening between years 2003 and 2004. The overall hrHPV prevalence rate was 7.5%. The peak prevalence at the age group of 25-29 was 24.1% decreasing steadily thereafter to approximately 2.9% in women aged 65 years. Young age and marital status were the main determinants for oncogenic HPV types. Our study confirms the inverse relationship between age and hrHPV prevalence reported in many developed countries. As our prevalence rates and hence background risk for cervical cancer are not lower than in other European countries, it is likely that our lowest cervical cancer burden in Europe is due to health care actions justifying the organised cervical cancer screening. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18566992
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [Predicting response to therapy in breast cancer]

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: [Predicting response to therapy in breast cancer]
To: mesothelioma77@gmail.com


[1]Gynakol Geburtshilfliche Rundsch. 2008; 48(3): 113-7
Strunz K, Deissler H, Kreienberg R, Sauer G

Molecular staging of breast cancer with microarray technologies leads to different gene expression profiles distinguishing 4 special groups: luminal A and B subtype, HER2 subtype and basal subtype. These 4 groups show a different prognosis as well as different behaviours and responses to adjuvant therapy. The development of gene expression profiles to classify breast cancer may contribute to the targeted institution of adjuvant therapies. Especially the 21-gene recurrence score (Oncotype DX) and the 70-gene profile (Mamma-print) have become intensively examined prognostic and predictive tools. As chemotherapy is an integral component of adjuvant therapy in early breast cancer but estrogen-receptor-positive breast cancer is the most common type, patient selection for adjuvant chemotherapy is of particular interest. In instances when the benefit from chemotherapy seems modest, there is a decision making tool beside traditional histopathological parameters that might provide additional objective prognostic and predictive information. Those genomic decision making approaches may yield more rational treatment choices and may keep patients from systemic treatment modalities of lower value.



___
Source: http://www.hubmed.org/display.cgi?uids=18566527
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells.
To: mesothelioma77@gmail.com


[1]J Immunol. 2008 Jul 1; 181(1): 808-21
Vasir B, Wu Z, Crawford K, Rosenblatt J, Zarwan C, Bissonnette A, Kufe D, Avigan D

Vaccination of patients with dendritic cell (DC)/breast carcinoma fusions stimulated antitumor immune responses in a majority of patients with metastatic disease but only a subset demonstrate evidence of tumor regression. To define the factors that limit vaccine efficacy, we examined the biological characteristics of DC/breast carcinoma fusions as APCs and the nature of the vaccine-mediated T cell response. We demonstrate that fusion of DCs with breast carcinoma cells up-regulates expression of costimulatory and maturation markers and results in high levels of expression of IL-12 consistent with their role as activated APCs. Fusion cells also express the chemokine receptor CCR7, consistent with their ability to migrate to the draining lymph node. However, DC/breast cancer fusions stimulate a mixed T cell response characterized by the expansion of both activated and regulatory T cell populations, the latter of which is characterized by expression of CTLA-4, FOXP3, IL-10, and the suppression of T cell responses. Our results demonstrate that IL-12, IL-18, and TLR 9 agonist CpG oligodeoxynucleotides reduce the level of fusion-mediated regulatory T cell expansion. Our results also demonstrate that sequential stimulation with DC/breast carcinoma fusions and anti-CD3/CD28 results in the marked expansion of activated tumor-specific T cells. These findings suggest that DC/breast carcinoma fusions are effective APCs, but stimulate inhibitory T cells that limit vaccine efficacy. In contrast, exposure to TLR agonists, stimulatory cytokines, and anti-CD3/CD28 enhances vaccine efficacy by limiting the regulatory T cell response and promoting expansion of activated effector cells.



___
Source: http://www.hubmed.org/display.cgi?uids=18566447
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Lung disease Amy Winehouse told to stop smoking drugs or die.

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Lung disease Amy Winehouse told to stop smoking drugs or die.
To: mesothelioma77@gmail.com

Warned she could die ... Amy Winehouse looks out the window of her North London home on June 11, 2008.

Mon, 23 Jun 2008 01:17:25 GMT

---

Source: http://www.theage.com.au/news/people/amy-winehouse-told-to-stop-smoking-drugs-or-die/2008/06/23/1214073097985.html
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Once-fatal cancers now treated as a chronic disease

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Once-fatal cancers now treated as a chronic disease
To: mesothelioma77@gmail.com

To see Barry Cooper working out at the YMCA in Brooklyn, New York, every morning before going to work as a patent lawyer, you would be unlikely to guess that he has cancer.

Sun, 22 Jun 2008 21:01:48 GMT

---

Source: http://www.iht.com/articles/2008/06/19/arts/snbrody.php
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Woman Who Won Millions From Wyeth In Cancer Suit Dies

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Woman Who Won Millions From Wyeth In Cancer Suit Dies
To: mesothelioma77@gmail.com

One of three Nevada women who were awarded millions in damages in a drug-company lawsuit has died.

Sun, 22 Jun 2008 20:05:33 GMT

---

Source: http://www.todaysthv.com/news/health/story.aspx?storyid=67892
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc